SWTX News and Press, SpringWorks Therapeutics Inc.

2024-05-14 09:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the BofA Securities 2024 Health Care Con...

2024-05-05 02:22:06 ET Start Time: 08:30 End Time: 09:06 SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Conference Call May 02, 2024, 08:30 AM ET Company Participants Saqib Islam - CEO Francis Perier - CFO Bhavesh Ashar - Chief Commercial Officer ...

2024-05-04 15:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-02 06:36:45 ET More on SpringWorks Therapeutics SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners SpringWorks Therapeutics jumps amid takeover sp...

– Achieved $21.0 million in OGSIVEO ® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated ...

2024-05-01 11:40:00 ET More on SpringWorks Therapeutics SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners SpringWorks Therapeutics jumps amid takeover sp...

2024-04-25 14:19:07 ET Summary SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully commercializing its therapy. With rapidly growing losses an...

– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO – STAMF...

2024-04-19 15:55:00 ET Summary SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo for the treatment of desmoid tumors in November last year. Ogsiveo is the first therapy approved for desmoid tumors, with a market opportunity estimated at ...